Authors
Latest:
Leveraging Immunotherapy in GI Malignancies: Looking to the FutureIn this episode of OncChats: Leveraging Immunotherapy in GI Malignancies, experts discuss next steps for research, including vaccination strategies, personalized cellular therapies, and more.
Latest:
Dr. Theurillat on Castration and AR Inhibition in Prostate CancerJean-Philippe Theurillat, MD, discusses castration and androgen receptor inhibition in prostate cancer.
Latest:
Dr. Kim on the Synergistic Effect of PD-1H Blockade in AMLTae Kon Kim, MD, PhD, discusses key results on the synergistic effects of PD-1H blockade in acute myeloid leukemia..
Latest:
Dr Ball on Prior Research Supporting the SELECT-AML-1 Trial in Newly Diagnosed AMLBrian C. Ball, MD, discusses previous research on tamibarotene in newly diagnosed acute myeloid leukemia, and how these data support the ongoing phase 2 SELECT-AML-1 trial.
Latest:
Breast Cancer Treatment: Sequencing With Antibody-Drug ConjugatesClinical pearls regarding ways to integrate antibody-drug conjugates into treatment algorithms when managing patients with breast cancer.
Latest:
Dr. Rose on the Importance of Genetic Testing in Ovarian CancerStephen L. Rose, MD, UW Health, discusses the importance of genetic testing in ovarian cancer.
Latest:
Dr. Concin on the Patient Population in the LIO-1 Trial in Advanced Gynecologic MalignanciesNicole Concin, MD, discusses the patient population that enrolled in the phase 1b/2 LIO-1 trial in advanced gynecologic malignancies.
Latest:
Endometrial Carcinoma: Clinical Case Scenario 3Oncologists debate the proper treatment of a patient with a grade 2 endometrial carcinoma tumor.
Latest:
Dr Noonan on Challenges Regarding the Sequencing and Selection of Therapies in HCCAnne M. Noonan, MBBCh, discusses unmet needs that remain to be addressed in hepatocellular carcinoma, including challenges regarding the navigation and sequencing of treatment options
Latest:
Dr. Seedor on Treatment Sequencing in Metastatic MelanomaRino S. Seedor, MD, discusses findings from the phase 3 DREAMseq trial, which solidified up-front immunotherapy followed by targeted therapy upon progression as a standard of care in patients with BRAF V600–mutant metastatic melanoma.
Latest:
Dr. Tseng on the Goal of the TARPSWG Analysis in Retroperitoneal SarcomaWilliam W. Tseng, MD, discusses the goals of the Transatlantic Australasian Retroperitoneal Sarcoma Working Group analysis in retroperitoneal sarcoma.
Latest:
Dr. Jain on Efficacy With Maintenance Avelumab Plus BSC in Metastatic Urothelial CancerRohit Jain, MD, MPH, discusses the data from the phase 3 JAVELIN Bladder 100 trial examining avelumab as maintenance therapy following response or stable disease with first-line platinum-based chemotherapy in patients with advanced or metastatic urothelial cancer.
Latest:
Dr. Devitt on Utilizing PD-L1 in Biomarker-Guided Therapies in Bladder CancerMichael Devitt, MD, discusses utilizing PD-L1 status in biomarker-guided therapies for patients with bladder cancer.
Latest:
Breast Nerve Preservation and Grafting: How Surgeons Can Help Mitigate Sensation LossMore surgeons are having in-depth conversations with their patients with breast cancer and prophylactic patients about the fact that nerves will have to be cut during their mastectomy, how that will impact sensation and quality of life, and how surgeon collaboration and breast neurotization can help restore sensation.
Latest:
Dr. Bordoni on the Utility of Adjuvant Atezolizumab in the Adjuvant Setting in NSCLCRodolfo Bordoni, MD, discusses the utility of atezolizumab in the adjuvant setting in non–small cell lung cancer.
Latest:
Dr Armenian on Improving Outcomes and Reducing AEs in Pediatric OncologySaro H. Armenian, DO, MPH, discusses treatment advancements that have helped reduce long-term adverse effects for patients in pediatric oncology.
Latest:
Dr. Schenk on the Effect of Nivolumab Plus Relatlimab in Basal Cell CarcinomaKara M. Schenk, MD, discusses the effect of nivolumab plus relatlimab in advanced basal cell carcinoma.
Latest:
Advice for Community Physicians Treating Patients with Neuroendocrine Tumor-Associated Carcinoid SyndromeDrs Das, Pommier, and Zacks share their advice for community physicians treating patients who have neuroendocrine tumors with carcinoid syndrome and carcinoid heart disease.
Latest:
Dr. Friedland on a Multimodal Screening Blood Test to Detect CRCShai Friedland, MD, discusses a multimodal screening blood test for advanced adenomas in colorectal cancer.
Latest:
Preparing and Delivering a Virtual Learning SessionStrategies are important to optimize learning in the virtual environment including speaker preparation, creating a virtual learning climate, and encouraging and enhancing interaction.
Latest:
Advice for New Nurse Practitioners Working With Patients With Endometrial CancerClosing their discussion, the panel shares advice for new nurse practitioners caring for patients who have endometrial cancer.
Latest:
Dr Manich on the ReDiscover Study of RLY-2608 in PIK3CA-Mutant Advanced Solid TumorsCristina Saura Manich, MD, PhD, discusses the phase 1 ReDiscover study evaluating RLY-2608 in patients with PIK3CA-mutated advanced breast cancer and other solid tumors.
Latest:
Wagner on the Investigation of Nab-Sirolimus in Advanced Malignant PEComaDr Wagner discusses unmet needs for patients with PEComa, ongoing research to address these gaps, and findings from the AMPECT trial.
Latest:
Dr Mathews on Maintenance Olaparib in Ovarian CancerCara A. Mathews, MD, discusses 7-year overall survival data from the phase 3 SOLO-1 trial in patients with ovarian cancer.
Latest:
Dr Sridhar on the Use of Zelenectide Pevedotin in Locally Advanced or Metastatic Urothelial CancerSrikala Sridhar, MD, MSc, FRCPC, discusses the unique application of zelenectide pevedotin, which targets nectin-4 in locally advanced or metastatic urothelial cancer.
Latest:
Current Treatment Options for Patients with Steroid-Refractory Acute GVHDClosing her discussion, Dr Pashna Munshi reviews recent data on the available treatment options for patients with steroid-refractory acute GVHD.
Latest:
Dr. Anne on the Practice-Changing Data of DESTINY-Breast04 in HER2-Low Breast CancerMadhurima Anne, MD, discusses the practice-changing data of the phase 3 DESTINY-Breast04 trial in patients with HER2-low breast cancer.
